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Breast cancer is the commonest cancer among women the world
over. In India, the reported age adjusted incidence of breast cancer
in women is about 26.7/1 00 000 population (NCRP, 1992).
Unlike the West, in India, majority of the patients (about 60%)
present with locally advanced breast cancer (LABC) or dissem-
inated disease (Goel et al, 1995). In LABC, the treatment policy
followed at most centres, is neoadjuvant chemotherapy (NACT)
followed by surgery and local or locoregional radiotherapy. The
response to NACT is assessed by clinical evaluation and supple-
mented by radiological measurement of reduction in tumour
volume by mammography and/or ultra sonography. None of the
currently available indicators of response (clinical and radiolo-
gical) correlate well with the actual response as assessed on
histopathological examination of the tumour. 
MR imaging (MRI) is a valuable new tool for diagnostic
mammography (Orel et al, 1996; Friedrich, 1998; Harms, 1998;
Orel, 1998). Recently, dynamic contrast enhanced MRI techniques
have also been developed for differentiation between benign 
and malignant tumours (Kaiser, 1991; Harms et al, 1993;
Haywang-Kobrunner et al, 1997; Piccoli, 1997; Daniel et al,
1998). The above techniques, however, do not provide any meta-
bolic/ biochemical information. On the contrary, magnetic reso-
nance spectroscopy (MRS) permits non-invasive detection of
metabolic (biochemical) differences between tumours and normal
tissues, and can also be used to monitor response to different 
treatment regimens. Recently, we have shown that in LABC, the
assessment of response to NACT can be made using water-to-fat
ratio calculated from volume localized proton MRS (Jagannathan
et al, 1998, 1999). In addition, we also reported the presence of
choline in a majority of the breast cancer patients (Jagannathan 
et al, 1998). 
In this study, results of evaluation of choline in LABC and its
response to NACT using in-vivo proton MRS are presented. The
objectives are: (i) to evaluate the potential of proton MRS in the
study of breast cancer, and (ii) to investigate further, the recent
observation of choline containing compounds in malignant breast
tissues and its response to NACT. To the best of our knowledge,
this is the first report assessing the response of breast cancer to
NACT in a large cohort of patients using in-vivo proton MRS. 
PATIENTS AND METHODS 
Patients 
67 women with cytologically confirmed infiltrating ductal carci-
noma (IDC) were recruited. Necessary clearance from the Institute
ethical committee and written informed consent were obtained
prior to examination from patients and controls. Patients were
evaluated clinically and tumour size was measured using Vernier
calipers. Metastatic workup included liver function tests, chest
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roentgenograms and ultrasound evaluation of the abdomen. Only
patients with locally advanced breast cancer were included in this
study. The relevant patient data are presented in Table 1. None of
the patients had previously been treated with either hormone,
chemotherapy or radiotherapy. Treatment protocol used was
NACT followed by surgery with local/locoregional radiotherapy.
All patients (of Groups II and III) received either 3 or 6 cycles of
chemotherapy and the details of the treatment schedule are as
given in Table 1. Patients were re-evaluated 2 weeks after the
completion of chemotherapy and the response to therapy was
assessed clinically including measurement of tumour size. MRS
was performed on: normal volunteers (controls, n = 16); Group I:
32 patients investigated one week before NACT only; Group II: 21
patients investigated one week after the completion of the 3rd or
6th cycle of NACT only; and Group III: 14 patients who were
followed sequentially (one week before therapy and one week
after completion of the 3rd or 6th cycle of NACT). One patient
was breast feeding at the time of MRS. In 18 patients, proton
spectra were also recorded from the unaffected contralateral breast
(pretherapy patients, 14 from Group I and 4 from Group III). In
addition, 14 cases with benign breast lesion were also studied. 
Fine needle aspiration biopsy (FNAB) samples (n = 3) from
Group I patients were collected in polypropylene vials containing
phosphate-buffered saline in D2O and immediately frozen in liquid
nitrogen. The samples were thawed, transferred into 5 mm NMR
tubes (~500 ml aliquots) and water suppressed proton spectra was
recorded at 400 MHz at 37˚C on the same day. Tumour specimens
from 6 patients of Group I were collected and perchloric acid
extract (PCA) of the specimen was prepared according to the
previously described procedure (Jagannathan and Sendhilvelan,
1993). Spectra of FNAB specimen and PCA extract of biopsy
tumour tissues were carried out mainly to confirm the presence of
TCho observed in in-vivo MRS. 
MRI/MRS measurements 
MRI/MRS was performed at 1.5 Tesla (MAGNETOM, Siemens)
using a standard bilateral surface receiver coil provided by the
manufacturer. The subjects were positioned prone with each breast
fitting into a cup of the surface coil, while the body coil was used
as transmitter. Following the scout image, T1-weighted sagittal
images were obtained using standard spin-echo sequence and fat
suppressed MR images in the transverse and coronal planes. Using
these images and depending on the tumour size, voxels of appro-
priate dimension (Table 1) were chosen and positioned well within
the tumour for further MRS study. 
In-vivo localized MRS was carried out using the STEAM
sequence (Frahm et al, 1987). Magnetic field shimming was
carried out both globally and over the voxel region prior to MRS.
Line-widths (LW) after voxel shimming corresponded typically to
10–25 Hz for the lipid peak in case of normal/control breast and
5–20 Hz for the water peak in patients with breast tumours. 32 to
64 scans with and without water suppression were collected using
an echo time TE = 135 ms and a repetition time TR = 3 s, with the
total acquisition time being around 2 to 4 minutes. The free induc-
tion decays were zero filled to 4 K data points with a Gaussian
broadening of 3 Hz before Fourier transformation. Chemical shifts
were reported using water as internal standard at 4.70 ppm. Only
the presence or absence of TCho is reported in this study and no
objective statistical criteria of the signal-to-noise ratio were used
for detection of TCho signal. Investigators performing MRS (NRJ,
MK) were not blinded to the pre-treatment clinical diagnosis.
However, the presence or absence of total choline resonance was
based on strict experimental criteria adopted, namely: (i) the LW
of the unsuppressed water peak to be around 5 to 20 Hz, and (ii)
the ratio of the water suppression ³ 20. If these 2 criteria were not
met, the data was discarded. The total study time per patient,
including imaging and spectroscopy, was between 60 and 75
minutes. 
Proton spectra of the FNAB (at 37˚C) and the PCA extracts 
(at 25˚C) were recorded at 400.13 MHz (Bruker, DRX). Chemical
shifts were referenced to an external TMS and D2O was used as a
solvent. 
Data analysis 
To compare the proportions between 2 groups of patients, Fisher’s
Exact Test was used. Pre- and post-therapy status of Group III
patients in relation to the presence of choline was compared using
McNemar’s test. Results were considered significant at 5% level
of significance (P < 0.05). To assess the sensitivity and specificity
of TCho before treatment in relation to histopathology, we
grouped pre-therapy patients of Groups I and III and compared
with 14 benign cases (fibroadenoma). Since the response to NACT
is seen to be effective at the end of 3rd cycle (Jagannathan et al,
1998), the data of patients who had 3 cycles and 6 cycles of
therapy were grouped together for the purpose of analysis. 
RESULTS AND DISCUSSION 
The proton spectrum (without water suppression – Figure 1A)
from an 8 ml voxel (Figure 1B) of normal breast tissue of a
Table 1 Summary of patient data 
TNM stage No. of patients Menopausal status  Av. age (yrs) Tumour sizea (cm2) MRS data Chemotherapy regimen 
Pre Post Voxel   LW (Hz) CAF CMF Pac + Epi 
size (ml)
T2N2/T3N0 7 4 3 46.6 ± 7.6 12–22 1–8 18.1 ± 3.9 5 1 1 
T3N1/N2 7 5 2 44.1 ± 7.8 9–52 3.4–8 10.8 ± 5.9 5 1 1 
T4bN0 19 12 7 46.1 ± 10.8  14–56 3.4–8 15.6 ± 6.0 11  5 3 
T4bN1/N2 34 20 14 42.1 ± 11.8 8–144 2.2–27 9.7 ± 4.0 26 7 1 
CMF = Cyclophosphamide, Methotrexate & 5-Flurouracil (5FU). All drugs given on 1st and 8th day of a 28 days cycle; CAF = Cyclophosphamide, adriamycin
(epirubicin/doxorubicin) and 5-FU. Cyclophosphamide and 5FU given on day 1 and day 8 of a 28 day cycle and doxorubicin on day 1 only; Pac+EPi = Paclitaxal
and epirubicin. All drugs given on day 1 of 21 days cycle. aTumour size as determined from clinical evaluation. The data represents the length ´ breadth
(minimum and maximum). 1018 NR Jagannathan et al 
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volunteer shows that resonances from lipid protons dominate.
Detailed assignments of other peaks are as given in the figure
caption. The spectrum shown in Figure 1 for a control subject is
also typical of spectra obtained from the contralateral unaffected
breast for all patients. However, it is observed that the spectra
depend on the distribution of amount of glandular and fatty breast
tissue inside the voxel. With increasing age, the amount of glandular
breast tissue decreases and hence, young women were selected as
volunteers in the present study to achieve spectra from glandular
tissue as well as fatty breast tissue. 
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Figure 1 (A) In-vivo localized proton MR spectrum acquired at TE = 135 ms
from an 8 ml voxel of 31-year-old normal female volunteer. Resonance
assignments are as follows: terminal methyl protons of glycerides at 0.9 ppm,
methylene [—(CH2)n—] protons of lipids at 1.3 ppm, methylene protons a to
carboxyl of glyceride chain at 2.2 ppm, diallylic CH2 protons at 2.5 ppm,
olefinic hydrogens and CH of glycerol backbone of lipids at 5.2 ppm, water at
4.7 ppm. (B) Spin-echo T1-weighted sagittal MR image showing the voxel
location 
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Figure 2 (A) T1-weighted sagittal MR image showing the voxel location.
(B) Proton MR spectrum at TE = 135 ms from the tumour (8 ml voxel) of a
65-year-old female (#43) suffering from infiltrating duct carcinoma. (C) Water
suppressed proton spectrum from an 8 ml voxel at TE = 135 ms of the same
patient showing choline resonance at 3.2 ppm In-vivo proton MRS in locally advanced breast cancer 1019
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Figures 2B and 3B show the representative unsuppressed proton
spectra from an 8 ml voxel of 2 IDC patients (voxel location in
Figures 2A and 3A). The spectra are seen to be different from the
normal breast tissue, the water peak dominating with a much lower
contribution from lipid protons. This observation is in line with the
general hypothesis that tumours have considerably higher water
content (Sijens et al, 1988; Gilligam et al, 1997; Jagannathan et al,
1998, 1999; Roebuck et al, 1998). Recently, we documented
elevated water-to-fat ratios (W/F) in malignant breast tissues
compared to normal breast tissues which showed a statistically
significant reduction in patients receiving NACT (Jagannathan 
et al, 1998, 1999). 
Figures 2C and 3C show the water suppressed spectra from an 8
ml voxel of the same patients. In addition to the residual water and
fat, a peak at 3.2 ppm due to choline-containing compounds, is
clearly seen. In few patients (n = 4, and in one volunteer), other
minor resonance in the 8 to 9.5 ppm region were also observed
(figure not shown). These were assigned to purine (ATP and GTP)
and pyrimidine (uridine and cytidine phosphates) nucleotides. The
presence of choline and the assignment of other minor resonances
were verified with the help of in-vitro proton spectra of PCA
extract of the breast tumor tissues (figure not shown) and FNAB
samples. Only the presence or absence of total choline is reported
in this paper following strict experimental criteria, as discussed
previously. It is our experience that with the use of such strict
experimental criteria, the quality of MR spectra obtained markedly
improved (with good signal-to-noise ratio), facilitating easy obser-
vation of total choline peak. Necessary experimental precau-
tionary measures as outlined earlier, were taken since the presence
of total choline may be affected by poor quality local shim, the
relative position of the voxel in relation to the surface coil sensi-
tivity and the size of the voxel used. 
To evaluate the utility of in-vivo MRS, spectra were recorded
for 25 patients (pre-therapy patients of Groups I and III) choosing
different regions of the breast which included both tumour and
non-tumour region. Figure 4A shows the typical unsuppressed MR
spectrum from a voxel which is shifted away (Figure 4B) from
tumour. The spectrum looks similar to Figure 1A of normal volun-
teer, indicating that this region contains normal breast tissue. In
addition, no choline was detected in patients (n = 11) where the
residual water signal was suppressed. These exercises confirmed
that the spectra recorded, reflect the pathological state of the tissue
and further validate the observation of choline in malignant breast
tissue. 2D/3D chemical shift imaging experiments should further
help in discriminating between normal and diseased portions of
the breast (Doyle et al, 1999). 
Table 2 presents group specific data with desired statistical
analysis. Accordingly, TCho was observed in 81% of the Group I
patients. For Group II, in 3 out of 21 cases (i.e. 14%), TCho was
observed. Table 3 presents the individual data of Group III patients
who were monitored sequentially. Total choline was observable in
10 out of 14 cases before treatment. Out of these 10, 7 showed no
or significantly reduced TCho, indicating good response to
chemotherapy as evidenced by clinical and histopathological
evaluation (see Table 3). 3 patients showed no histopathological
response to chemotherapy, however, MRS showed significantly
reduced TCho in one (#69) and no TCho signal in the other 
2 patients (#70 and 81). In another patient (#77) TCho was not
observed before treatment, but was detected at the end of 3rd
cycle. This anomally could not be rationalized at this point. The
post-therapy histopathological investigations of Group III patients
correlated well (~80%–11 out of 14 showed concordance) with
the presence or absence of choline (Tables 3 and 4). Rapid
decrease of phosphomonoesters (one of these is phosphocholine)
has been observed in 31P MRS study of breast carcinoma during
effective chemotherapy (Glaholm et al, 1989; Leach et al, 1998). 
Further statistical analysis revealed that pre-therapy patients of
Groups I and III are comparable in relation to the presence of
TCho (P = 0.31). Similarly, the post-therapy status of patients in
relation to the absence of TCho are comparable between Groups II
and III (P = 0.67). The presence of TCho before initiation 
of NACT was compared with the histopathological diagnosis 
(Table 4). Of the 14 benign lesions studied, only 2 showed choline.
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Figure 3 (A) T1-weighted sagittal MR image showing the voxel location. 
(B) Proton MR spectrum at TE = 135 ms from the tumour (8 ml voxel) of a 
49-year-old female (#70) suffering from infiltrating ductal carcinoma of the
breast. (C) Water suppressed spectrum at 135 ms echo time 1020 NR Jagannathan et al 
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The sensitivity of in-vivo MRS in detecting TCho was 78% and
the specificity was 86%. In comparison, contrast-enhanced MRI
has a high sensitivity (93–99%) but a lower specificity (37–85%)
for detecting the breast cancer (Harms et al, 1993; Bone et al,
1997; Heywang-Kobrurner et al, 1997). However, the advantage
of in-vivo MRS is that it provides the biochemical/metabolic infor-
mation which is not available from contrast MRI. 
An interesting observation of this study, is the presence of TCho
from the contralateral unaffected breast of a patient who was
lactating at the time of MRS. Figure 5 shows TCho as well as
lactose peak around 3.8 ppm in this patient. Recently, Gribbested
et al (1998) and Kvisted et al (1999) have also observed choline in
the normal breast of lactating women as well in 2 out of 11 benign
lesions. An increase in phosphomonoester peak in lactating
women has also been documented by Twelves et al (1994) through
31P MRS. Payne et al (1994) have documented that the level of
phosphomonoesters changes significantly in normal breast tissues
during menstrual cycle. Absolute concentration of choline in
breast lesions through in-vivo proton MRS have been determined
(Roebuck et al, 1998). Mackinnon et al (1997) reported elevation
of choline levels in malignant breast tumours compared to benign
cases from in-vivo NMR of FNAB samples and evaluated its
sensitivity and specificity in distinguishing benign lesions from
invasive cancer. Of the various choline containing compounds
that contribute to the peak at 3.2 ppm in in-vivo MRS (choline,
glycerophosphocholine and phosphocholine), an increase in
Table 2 Group specific distribution of patients in relation to the presence of choline along with its percentage and 95%
confidence interval (CI) 
Groups
I II III 
Pre Post Pre Post 
Number of patients with choline 26 3 10  1 
Number of patients with significantly reduced or no choline  6 18 4 13 
% of patients with choline 81 14 71 7 
95% Confidence 68–95 0–29 48–95 0–18 
Figure 4 (A) Proton spectrum acquired at an echo time of 135 ms from an
8 ml voxel shifted away from tumour of the same patient shown in Figure 3. 
(B) The corresponding voxel location in the T1-weighted sagittal MR image 
Figure 5 Proton spectrum from the unaffected contralateral normal breast
tissue of a patient who was breast feeding at the time of MRS 
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phosphocholine is highly probable (Katz-Brull et al, 1998;
Roebuck et al, 1998). 
The phosphocholine (PC) and phosphoethanolamine (PE) are
the precursors in the synthesis of phosphatidylcholine (PCho)
and phosphatidylethanolamine (PEth), respectively, and are also
degradation products of phospholipid breakdown by phospholi-
pase C. Several NMR studies have revealed high concentrations
of phosphomonoesters (PC and PE) in human breast tumors
(Sijens et al, 1988; Merchant et al, 1988; Glaholm et al, 1989;
Degani, 1994; Katz-Brull et al, 1998; Leach et al, 1998). Smith 
et al (1991) have shown a strong association between the prolif-
eration rate of a rat mammary tumour and the PC and GPC
content of the tumour. Gribbestad et al (1993, 1994) reported that
PCho showed a large variation between the same type of tumours
suggesting breast tumours might have very different choline
content. This may be the likely reason for choline to be detected
in only 80% of patients studied by us before treatment. Recently,
Singer et al (1995) have observed ~18-fold increase in phospho-
choline content in 2 primary breast cancer lines (21PT and
21NT), and a 27-fold increase in the metastatic breast cancer cell
line (21MT-2) compared with the normal breast epithelial cell
line 76N. This increase was accounted for by a decrease in the
CTP: cytidylyltransferase activity and/or by increase in choline
kinase activity (Merchant et al, 1988). The metastatic breast
cancer cell line 21MT-2 also has a significantly higher concentra-
tion of PC than do the primary breast cancer cell lines. Recently,
Katz-Brull et al (1998) have documented through NMR a
biochemical basis for the presence of high phosphocholine in
breast carcinoma relative to benign tumours and normal breast
tissues. 
CONCLUSIONS 
In conclusion, our study demonstrates the utility of volume local-
ized in-vivo proton MR spectroscopy in the study of locally
advanced breast cancer. The important finding of this study is the
observation of TCho in 78% of the patients prior to therapy. 
In patients receiving NACT, absence/reduction of TCho was
observed in 89% of the patients (31 out of 35 cases of Groups II
and III showed no or reduced TCho – see Tables 2 and 3). Our
results indicate that the detection of TCho in malignant tumours
from in-vivo proton MRS has a good sensitivity (~80%) and speci-
ficity (86%). Further studies involving methods to quantitate
TCho might be of value for differentiation of breast tumours. Such
observations open up the possibility of assessing noninvasively the
changes in the concentration of the individual metabolites and
their relation with the tumour behaviour, progression, pathophysi-
ology and treatment. The potential clinical use of in-vivo MRS in
the management of a patient with breast cancer especially in
preoperative diagnosis needs further evaluation. The results
presented here, however, have shown that this technique is useful
to assess the response of LABC to neuoadjuvant chemotherapy. In
Table 3 Individual clinical and MRS data of Group III patients who were monitored sequentially 
S. No. Patient No. Age (yrs) Tumour stage  Tumour size (cm) Presence of choline Clinical response Histopath. response 
Pre Post
14 33 5 T 4bN2M0 9 ´ 8 Yes No R R 
24 42 8 T 4bN2M0 8 ´ 8 Yes No R R 
34 73 5 T 4bN1M0 11 ´ 8 Yes Yes ¯ RR  
45 03 5 T 3N2M1 8 ´ 6.5 No No R R 
56 05 5 T 3N1M0 6 ´ 4.5 Yes Yes ¯ RR  
66 13 0 T 4bN2M0 3.4 ´ 2.3 No No R R 
76 76 6 T 4bN1M0 5 ´ 5N o N o R R  
86 92 6 T 4bN2M1 12 ´ 12 Yes Yes ¯ NR NR 
97 03 3 T 4bN2M0 6 ´ 5 Yes No NR NR 
10 77 23 T4bN1M0 8 ´ 7 No Yes R R 
11 79 43 T4cN2M0 18 ´ 17 Yes No R R 
12 81 40 T4bN1M0 9 ´ 8 Yes No NR NR 
13 85 32 T4bN2M0 7 ´ 6.5 Yes No R R 
14 88 40 T4bN2M0 8 ´ 6 Yes No R R 
R = corresponds to response to chemotherapy; NR = corresponds to no response to chemotherapy. 
Table 4 Comparison of MRS results with histopathology 
Choline from MRS IDC* (Groups I and III) and benign casesa After chemotherapy treatment in Group III patients (n = 14) 
IDC (pre-therapy) (n = 46) Benign (n = 14) Respondersa Non-respondersa
Present 36 2 1 1 
Absent 10 12 10 2 
aConfirmed by histopathological evaluation. Note: The sensitivity of in-vivo MR spectroscopy was 78% (36 true positive findings of TCho before therapy, out of
46 total findings), the specificity was 89% [12 true negative findings (benign cases) of 14 total findings]. 1022 NR Jagannathan et al 
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addition, as discussed earlier, at our centre a large number patients
present with LABC and accurate assessment of the response to
treatment by MRS may help in selecting patients for breast conser-
vation. 
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